Protalix BioTherapeutics, Inc. (PLX) intrinsic value & 10-year financials
Protalix BioTherapeutics, Inc. (PLX) has a Graham intrinsic value of $1.33 per share. At $2.62 on Oct 17, 2026, the stock trades 97% above that value. Over the last 10 fiscal years revenue grew 21.4% a year to $52.7M, with an average return on invested capital of -6.8%.
- Graham intrinsic value
- $1.33
- Share price (Oct 17, 2026)
- $2.62
- Price vs Graham value
- 97% above
- Market cap
- $205.8M
- Revenue (FY2025)
- $52.7M
- Revenue growth (10-yr CAGR)
- 21.4%
- ROIC (10-yr avg)
- -6.8%
- Free cash flow (FY2025)
- -$13.6M
PLX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $52.7M | -$6.6M | -$0.08 | -$13.6M | -10.4% | -16.2% |
| FY2024 | $53.4M | $2.9M | $0.04 | $7.4M | 7.3% | 13.2% |
| FY2023 | $65.5M | $8.3M | $0.09 | -$2.5M | 16.0% | -224.9% |
| FY2022 | $47.6M | -$14.9M | -$0.31 | -$25.6M | -27.3% | 40.5% |
| FY2021 | $38.4M | -$27.6M | -$0.62 | -$11.7M | -53.4% | 71.3% |
| FY2020 | $62.9M | -$6.5M | -$0.22 | -$26.8M | 4.3% | 11.2% |
| FY2019 | $54.7M | -$18.3M | -$0.61 | -$20.0M | -19.6% | 21.5% |
| FY2018 | $34.2M | -$26.5M | — | -$8.4M | -56.4% | 29.2% |
| FY2017 | $19.2M | -$85.3M | — | -$11.0M | -188.9% | — |
| FY2016 | $9.2M | -$29.4M | — | -$32.9M | -360.5% | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Protalix BioTherapeutics, Inc. is a consistent compounder, expanding top-line revenue at 21.4% annually over the past decade.
Protalix BioTherapeutics, Inc. has earned high returns on invested capital, averaging 21.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Protalix BioTherapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Protalix BioTherapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1.33 per share.